Segall Bryant & Hamill, LLC Alkermes Plc. Transaction History
Segall Bryant & Hamill, LLC
- $6.35 Billion
- Q1 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 528,821 shares of ALKS stock, worth $15.8 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
528,821
Previous 569,620
7.16%
Holding current value
$15.8 Million
Previous $16.4 Million
6.59%
% of portfolio
0.28%
Previous 0.23%
Shares
21 transactions
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$870 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$545 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$352 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$240 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$206 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.91B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...